Developing the first non-hormonal therapeutic for endometriosis
Endometriosis has been considered the greatest overlooked epidemic in women’s health. At least 10% of girls and women worldwide have endometriosis, affecting all ethnicities alike. It is the leading cause of female infertility, chronic pelvic pain, and gynecologic surgeries.
Shockingly, to date, there is no cure for endometriosis. The current management protocols include hormone and pain therapies which still fail to reverse the disease or address the root cause. Patients must often resort to surgery, leaving the possibility for reoccurrence.
As the number one cause of disability in women in their reproductive years, endometriosis is currently affecting over 176 million women worldwide and their ability to work, parent, or simply enjoy life.
Why It Matters
Straight to the Cause
EndoCyclic Therapeutics is developing a treatment for endometriosis that addresses the root cause of the disease. We aim to give women afflicted by endometriosis the chance to finally enjoy remission from this painful disease.
We are developing revolutionary molecules that can invade endometriosis disease cells at the source. These molecules are “first-in-class” and bind to directly to non-hormonal targets.
Thorough Research Methodology
We have discovered a new biochemical pathway that triggers endometriosis. We are designing novel targeted therapeutics that disrupt disease initiation without the use of hormones.
Helping Women Live
At EndoCyclic Therapeutics, our mission is to stop the suffering of millions of women - and their families - who are affected by endometriosis.
Our team includes the top talent from medicine, biology, chemistry, bioinformatics, and engineering who have come together to focus their energies on this serious women health issue. Our goal is to liberate millions of women from the pain and infertility caused by endometriosis.
ENDOMETRIOSIS RESEARCH TO DEVELOP NON-INVASIVE TREATMENT AND DIAGNOSIS
"The company’s lab, supported by an NICHD small business grant, is cultivating tiny molecules that invade and kill endometrial cells at the source, stopping them from spreading and growing painful lesions."
ALUMNA CREATES COMPANY TO DEVELOP NONHORMONAL ENDOMETRIOSIS TREATMENT
“I like to say that endometriosis attacked the wrong girl, because we’re fighting back,” Petrossian said. “A disease that attacks 10 percent of our girls and women worldwide attacks all of us, so let’s wipe it out.”
Whether you are a patient, physician, advocate, academic, investor, or potential industry partner, we want to hear from you. Contact us to see how you can get involved.
Address: 5270 California Ave, Suite 300 Irvine, CA 92617
*At this time, we are not actively hiring. Please be aware that any job listings found on external platforms are not affiliated with our organization. We encourage you to visit our website regularly for updates on future opportunities, as all official job openings will be posted here. Thank you for your interest in joining our team!